<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109118">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01698164</url>
  </required_header>
  <id_info>
    <org_study_id>2008BAI57B04</org_study_id>
    <nct_id>NCT01698164</nct_id>
  </id_info>
  <brief_title>Multi-centre Clinical Trial on Hormone Replacement Treatment in China</brief_title>
  <official_title>Multi-centre Clinical Trial on Hormone Replacement Treatment in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the benefit/risk of  hormone replacement treatment among early
      menopausal women in China. This is a multi-centre, random, prospective study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in risk factors of cardiovascular disease at 12 months and 24 months</measure>
    <time_frame>before the treatment, time point of taking the medicine for 1 year, time point of taking the medicine for 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>lipid profiles, high-sensitivity C-reactive protein, Hemoglobin A1C, fasting glucose, fasting insulin, blood pressure, waistline, hipline, body composition, electrocardiogram, incidence of coronary heart disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in risk factors of breast cancer at 12 months and 24 months</measure>
    <time_frame>before the treatment, time point of taking the medicine for 1 year, time point of taking the medicien for 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mammography, palpation of breast, incidence of breast cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in BMD at 12 months and 24 months</measure>
    <time_frame>before the treatment, time point of taking the medicine for 1 year, time point of taking the medicien for 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>DEXA bone mineral density</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in risk factors of senile dementia every three months</measure>
    <time_frame>before the recruitment, before handing out the mecidcine, every three months after taking the medicine till two years later</time_frame>
    <safety_issue>No</safety_issue>
    <description>mini-mental state examination, hospital anxiety and depression scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the quality of life every three months</measure>
    <time_frame>before the recruitment, before handing out the mecidcine, every three months after taking the medicine till two years later</time_frame>
    <safety_issue>No</safety_issue>
    <description>Kupperman menopause index, RAND36 Menopause-Specific quality of life questionaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline in thickness of endometrium at 12 months and 24 months</measure>
    <time_frame>before the treatment, time point of taking the medicine for 1 year, time point of taking the medicien for 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ultrasonography</description>
  </other_outcome>
  <other_outcome>
    <measure>uterine bleeding</measure>
    <time_frame>every three months after taking the medicine until two years later</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>diary</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in vital signs every three months</measure>
    <time_frame>before the recruitment, before handing out the mecidcine, every three months after taking the medicine till two years later</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>height, weight, heart rate, BP, gynecological examination</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in general health at 12 months and 24 months</measure>
    <time_frame>before the treatment, time point of taking the medicine for 1 year, time point of taking the medicien for 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>liver function, renal function</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Menopausal Syndrome</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Osteoporosis</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>estradiol plus MPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 4mg medroxyprogesterone acetate, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.
estradiol valerate, 1mg*21/box medroxyprogesterone acetate, 2mg*100/bottle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>estradiol plus progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 200mg progesterone capsule, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.
estradiol valerate, 1mg*21/box progesterone capsule, 100mg*6/box</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ximingting tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet of cimicifuga rhizoma extract, tid 100mg*15*2/box The anticipated duration is 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estradiol plus MPA</intervention_name>
    <description>Participants are given estradiol and synthetic progestin.</description>
    <arm_group_label>estradiol plus MPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ximingting Tablet</intervention_name>
    <description>Participants are given phytoestrogen.</description>
    <arm_group_label>Ximingting tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estradiol plus progesterone</intervention_name>
    <description>Participants are given estradiol and natural progesterone.</description>
    <arm_group_label>estradiol plus progesterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  going through amenorrhea above 6 months and within 5 years,

          -  aged 40 to 60 years,

          -  going though postmenopausal symptoms,

          -  serum E2 concentration &lt;30pg/ml,

          -  serum FSH concentration &gt;40IU/L.

        Exclusion Criteria:

          -  uterine fibroid diameter≥5cm,

          -  history of diabetes or hypertension,

          -  history of thromboembolism, severe endometriosis, epilepsy, asthma,
             hyperprolactinemia,

          -  first degree relative had a history of breast cancer,

          -  being in severe or unstable condition of somatic diseases,

          -  receiving HRT in the past 3 month,

          -  drug or alcohol abuse in the past 3 month,

          -  endometrial thickness ≥0.5cm after withdrawal bleeding,

          -  being allergic to the medicine,

          -  participating in other clinical trials within 1 month ago.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aijun Sun, PH.D   M.D</last_name>
    <role>Study Director</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tingping Zheng, Bachelor Degree</last_name>
    <email>zhengtingping@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PUMCH</name>
      <address>
        <city>Peking</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Xue, Bachelor Degree</last_name>
      <email>xuewei8955@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 28, 2012</lastchanged_date>
  <firstreceived_date>September 25, 2012</firstreceived_date>
  <keyword>lipid profiles</keyword>
  <keyword>coronary heart disease</keyword>
  <keyword>menopausal syndrome</keyword>
  <keyword>MMSE</keyword>
  <keyword>MENQOL</keyword>
  <keyword>HAD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
